| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 189 | 2024 | 16718 | 7.460 |
Why?
|
| South Africa | 139 | 2023 | 1731 | 5.770 |
Why?
|
| Anti-HIV Agents | 44 | 2022 | 4256 | 4.430 |
Why?
|
| HIV-1 | 86 | 2022 | 6939 | 4.040 |
Why?
|
| Adenine | 22 | 2015 | 936 | 3.960 |
Why?
|
| HIV Antibodies | 39 | 2022 | 1322 | 3.490 |
Why?
|
| Acquired Immunodeficiency Syndrome | 20 | 2023 | 2232 | 3.010 |
Why?
|
| Anti-Retroviral Agents | 25 | 2022 | 1715 | 2.980 |
Why?
|
| Tuberculosis | 22 | 2021 | 1912 | 2.940 |
Why?
|
| Antibodies, Neutralizing | 38 | 2024 | 1978 | 2.580 |
Why?
|
| Vagina | 21 | 2022 | 825 | 2.400 |
Why?
|
| HIV Seropositivity | 14 | 2022 | 971 | 2.350 |
Why?
|
| Sexually Transmitted Diseases | 21 | 2023 | 624 | 2.330 |
Why?
|
| AIDS-Related Opportunistic Infections | 10 | 2015 | 657 | 2.120 |
Why?
|
| Anti-Infective Agents | 13 | 2017 | 972 | 1.970 |
Why?
|
| Vaginosis, Bacterial | 8 | 2022 | 128 | 1.930 |
Why?
|
| Antitubercular Agents | 13 | 2017 | 1320 | 1.900 |
Why?
|
| AIDS Vaccines | 19 | 2022 | 938 | 1.820 |
Why?
|
| Viral Load | 41 | 2022 | 3299 | 1.740 |
Why?
|
| Herpes Genitalis | 5 | 2015 | 141 | 1.540 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2018 | 615 | 1.500 |
Why?
|
| Vaginitis | 5 | 2019 | 47 | 1.420 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 11 | 2017 | 63 | 1.390 |
Why?
|
| Medication Adherence | 7 | 2015 | 2063 | 1.370 |
Why?
|
| Epidemics | 5 | 2019 | 523 | 1.340 |
Why?
|
| Genitalia, Female | 8 | 2021 | 146 | 1.340 |
Why?
|
| Anti-Infective Agents, Local | 7 | 2016 | 250 | 1.340 |
Why?
|
| Clinical Trials as Topic | 18 | 2021 | 7913 | 1.110 |
Why?
|
| Antibodies, Monoclonal | 14 | 2023 | 9274 | 1.060 |
Why?
|
| HIV | 13 | 2023 | 1604 | 1.010 |
Why?
|
| Herpesvirus 2, Human | 4 | 2015 | 189 | 1.010 |
Why?
|
| Cytokines | 21 | 2021 | 7322 | 0.990 |
Why?
|
| Rural Health Services | 3 | 2017 | 379 | 0.970 |
Why?
|
| Rural Population | 17 | 2015 | 2210 | 0.960 |
Why?
|
| CD4 Lymphocyte Count | 19 | 2022 | 2559 | 0.940 |
Why?
|
| Trichomonas Vaginitis | 3 | 2018 | 35 | 0.940 |
Why?
|
| Hepatitis B virus | 4 | 2019 | 513 | 0.930 |
Why?
|
| Public Health | 6 | 2023 | 2603 | 0.890 |
Why?
|
| Rifampin | 4 | 2014 | 315 | 0.890 |
Why?
|
| Superinfection | 4 | 2018 | 65 | 0.880 |
Why?
|
| Gels | 10 | 2020 | 427 | 0.880 |
Why?
|
| Cervix Uteri | 7 | 2020 | 590 | 0.870 |
Why?
|
| Hepatitis B | 7 | 2019 | 695 | 0.870 |
Why?
|
| HIV Envelope Protein gp120 | 15 | 2020 | 952 | 0.870 |
Why?
|
| Africa | 10 | 2021 | 673 | 0.870 |
Why?
|
| Humans | 284 | 2024 | 744343 | 0.850 |
Why?
|
| Pregnancy Complications, Infectious | 11 | 2022 | 2026 | 0.840 |
Why?
|
| Benzoxazines | 2 | 2015 | 301 | 0.830 |
Why?
|
| Naphthalenesulfonates | 3 | 2011 | 15 | 0.830 |
Why?
|
| Immunization, Passive | 5 | 2022 | 623 | 0.830 |
Why?
|
| Sexual Behavior | 16 | 2018 | 2057 | 0.780 |
Why?
|
| Trichomonas vaginalis | 4 | 2023 | 76 | 0.770 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2023 | 629 | 0.750 |
Why?
|
| Female | 181 | 2023 | 380194 | 0.750 |
Why?
|
| Immunization Programs | 3 | 2021 | 260 | 0.750 |
Why?
|
| Administration, Intravaginal | 10 | 2019 | 150 | 0.750 |
Why?
|
| Immune Evasion | 6 | 2021 | 360 | 0.730 |
Why?
|
| Sexual Partners | 6 | 2018 | 730 | 0.730 |
Why?
|
| Uterine Cervicitis | 3 | 2016 | 30 | 0.700 |
Why?
|
| HIV Seronegativity | 3 | 2015 | 211 | 0.690 |
Why?
|
| Drug Resistance, Viral | 5 | 2019 | 820 | 0.660 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2021 | 1873 | 0.650 |
Why?
|
| CD4-Positive T-Lymphocytes | 17 | 2021 | 4386 | 0.650 |
Why?
|
| Chemokines | 3 | 2022 | 970 | 0.630 |
Why?
|
| Infectious Disease Transmission, Vertical | 8 | 2022 | 1320 | 0.630 |
Why?
|
| Women's Health Services | 2 | 2014 | 93 | 0.630 |
Why?
|
| Epitopes | 17 | 2022 | 2571 | 0.620 |
Why?
|
| Communicable Disease Control | 3 | 2021 | 857 | 0.620 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3133 | 0.620 |
Why?
|
| Quarantine | 1 | 2020 | 170 | 0.620 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3240 | 0.620 |
Why?
|
| Antiviral Agents | 5 | 2019 | 2987 | 0.610 |
Why?
|
| Neutralization Tests | 11 | 2022 | 758 | 0.600 |
Why?
|
| Abortion, Spontaneous | 2 | 2022 | 544 | 0.600 |
Why?
|
| Mucous Membrane | 6 | 2021 | 673 | 0.580 |
Why?
|
| RNA, Viral | 9 | 2019 | 2902 | 0.580 |
Why?
|
| Disease Outbreaks | 5 | 2020 | 1772 | 0.570 |
Why?
|
| Research Design | 7 | 2017 | 5987 | 0.560 |
Why?
|
| Adult | 105 | 2023 | 214055 | 0.540 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 4 | 2021 | 307 | 0.530 |
Why?
|
| Incidence | 24 | 2020 | 20947 | 0.530 |
Why?
|
| Condoms | 10 | 2019 | 323 | 0.530 |
Why?
|
| Urban Health Services | 2 | 2014 | 179 | 0.530 |
Why?
|
| Young Adult | 48 | 2023 | 56430 | 0.530 |
Why?
|
| Pandemics | 5 | 2023 | 8388 | 0.520 |
Why?
|
| Communicable Diseases | 2 | 2023 | 880 | 0.520 |
Why?
|
| Family Planning Services | 3 | 2014 | 263 | 0.520 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2012 | 104 | 0.510 |
Why?
|
| Vaginal Discharge | 3 | 2012 | 25 | 0.500 |
Why?
|
| Polymers | 3 | 2011 | 1621 | 0.480 |
Why?
|
| Rectum | 1 | 2019 | 904 | 0.480 |
Why?
|
| Social Medicine | 1 | 2014 | 62 | 0.480 |
Why?
|
| Genital Diseases, Female | 2 | 2015 | 197 | 0.470 |
Why?
|
| Organic Anion Transporters | 1 | 2014 | 100 | 0.470 |
Why?
|
| Vaccines | 4 | 2023 | 822 | 0.470 |
Why?
|
| Isoniazid | 1 | 2015 | 274 | 0.460 |
Why?
|
| Pregnancy Rate | 2 | 2022 | 643 | 0.460 |
Why?
|
| Terminology as Topic | 1 | 2021 | 1547 | 0.460 |
Why?
|
| Directive Counseling | 1 | 2015 | 166 | 0.450 |
Why?
|
| Sickness Impact Profile | 1 | 2014 | 302 | 0.450 |
Why?
|
| Gonorrhea | 3 | 2023 | 335 | 0.440 |
Why?
|
| Virus Replication | 10 | 2021 | 2534 | 0.440 |
Why?
|
| HIV Seroprevalence | 6 | 2012 | 86 | 0.420 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 66 | 0.420 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 675 | 0.390 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2022 | 323 | 0.390 |
Why?
|
| Binding Sites, Antibody | 3 | 2017 | 349 | 0.380 |
Why?
|
| Politics | 3 | 2014 | 791 | 0.380 |
Why?
|
| Human Rights | 1 | 2014 | 307 | 0.380 |
Why?
|
| Acrylic Resins | 1 | 2011 | 142 | 0.380 |
Why?
|
| Drug Administration Schedule | 8 | 2015 | 4933 | 0.380 |
Why?
|
| Truth Disclosure | 1 | 2015 | 436 | 0.380 |
Why?
|
| Informed Consent | 3 | 2014 | 995 | 0.360 |
Why?
|
| Antibodies, Viral | 9 | 2024 | 3176 | 0.360 |
Why?
|
| HIV Envelope Protein gp41 | 5 | 2022 | 314 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2023 | 9959 | 0.350 |
Why?
|
| Chlamydia Infections | 3 | 2023 | 365 | 0.350 |
Why?
|
| Carrier State | 1 | 2013 | 518 | 0.350 |
Why?
|
| Adolescent | 46 | 2022 | 85781 | 0.340 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 393 | 0.330 |
Why?
|
| Criminal Law | 2 | 2020 | 96 | 0.330 |
Why?
|
| Self Care | 1 | 2014 | 786 | 0.330 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 249 | 0.330 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 5 | 2019 | 370 | 0.320 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 841 | 0.320 |
Why?
|
| Deoxycytidine | 1 | 2012 | 826 | 0.310 |
Why?
|
| Urban Population | 5 | 2014 | 2021 | 0.310 |
Why?
|
| Health Planning | 1 | 2009 | 238 | 0.310 |
Why?
|
| Lymphocyte Activation | 7 | 2019 | 5524 | 0.300 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 1177 | 0.300 |
Why?
|
| Disease Notification | 2 | 1999 | 97 | 0.300 |
Why?
|
| Vaccination | 9 | 2023 | 3278 | 0.300 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2020 | 279 | 0.300 |
Why?
|
| Child Health Services | 4 | 1997 | 667 | 0.290 |
Why?
|
| Inflammation | 6 | 2021 | 10638 | 0.290 |
Why?
|
| Cohort Studies | 26 | 2022 | 40561 | 0.290 |
Why?
|
| HIV Envelope Protein gp160 | 2 | 2019 | 99 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2015 | 6538 | 0.280 |
Why?
|
| Adaptation, Psychological | 2 | 2014 | 2576 | 0.280 |
Why?
|
| Socioeconomic Factors | 8 | 2015 | 7785 | 0.280 |
Why?
|
| Placebos | 4 | 2017 | 1676 | 0.280 |
Why?
|
| Developing Countries | 7 | 2006 | 2815 | 0.280 |
Why?
|
| Health Priorities | 1 | 2009 | 380 | 0.280 |
Why?
|
| Contraceptive Agents, Female | 2 | 2020 | 135 | 0.280 |
Why?
|
| Medicine, African Traditional | 2 | 1998 | 29 | 0.270 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 4 | 2017 | 222 | 0.270 |
Why?
|
| Measles | 3 | 1993 | 168 | 0.270 |
Why?
|
| Male | 63 | 2022 | 350118 | 0.270 |
Why?
|
| Disease Progression | 13 | 2022 | 13284 | 0.270 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 2219 | 0.270 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2010 | 482 | 0.270 |
Why?
|
| Epitope Mapping | 6 | 2019 | 311 | 0.270 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 39050 | 0.260 |
Why?
|
| Prevalence | 18 | 2022 | 15226 | 0.260 |
Why?
|
| Delayed-Action Preparations | 2 | 2022 | 968 | 0.260 |
Why?
|
| Interferon-gamma | 7 | 2016 | 3206 | 0.260 |
Why?
|
| Safe Sex | 2 | 2018 | 141 | 0.250 |
Why?
|
| Social Stigma | 1 | 2011 | 701 | 0.250 |
Why?
|
| Polysaccharides | 3 | 2017 | 1053 | 0.250 |
Why?
|
| Pregnancy | 22 | 2022 | 29144 | 0.240 |
Why?
|
| Bacteria | 3 | 2021 | 2114 | 0.240 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 4328 | 0.240 |
Why?
|
| Treatment Failure | 2 | 2022 | 2618 | 0.240 |
Why?
|
| Vaginal Douching | 2 | 2015 | 14 | 0.240 |
Why?
|
| Disease Susceptibility | 6 | 2018 | 1782 | 0.230 |
Why?
|
| Coitus | 2 | 2014 | 133 | 0.230 |
Why?
|
| Laboratory Infection | 1 | 2023 | 7 | 0.230 |
Why?
|
| Toll-Like Receptors | 3 | 2020 | 592 | 0.230 |
Why?
|
| Biomedical Research | 3 | 2023 | 3309 | 0.230 |
Why?
|
| Prospective Studies | 18 | 2022 | 53288 | 0.230 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2014 | 912 | 0.230 |
Why?
|
| Hepatitis A | 2 | 1994 | 133 | 0.230 |
Why?
|
| Counseling | 6 | 2020 | 1523 | 0.230 |
Why?
|
| Immunity, Mucosal | 3 | 2017 | 490 | 0.220 |
Why?
|
| Alkynes | 2 | 2015 | 306 | 0.220 |
Why?
|
| HLA-B Antigens | 3 | 2018 | 353 | 0.220 |
Why?
|
| United Nations | 2 | 2018 | 165 | 0.220 |
Why?
|
| Quality of Life | 2 | 2014 | 12804 | 0.220 |
Why?
|
| Genitalia | 2 | 2022 | 112 | 0.210 |
Why?
|
| Rural Health | 6 | 2007 | 305 | 0.210 |
Why?
|
| Treatment Outcome | 18 | 2022 | 63114 | 0.210 |
Why?
|
| Alanine | 2 | 2022 | 572 | 0.210 |
Why?
|
| Cross Protection | 1 | 2022 | 24 | 0.210 |
Why?
|
| Cyclopropanes | 2 | 2015 | 416 | 0.210 |
Why?
|
| Immunoglobulin G | 6 | 2020 | 4560 | 0.210 |
Why?
|
| Mutation | 11 | 2021 | 29786 | 0.210 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2017 | 570 | 0.200 |
Why?
|
| Federal Government | 1 | 2023 | 260 | 0.200 |
Why?
|
| Emigration and Immigration | 2 | 2003 | 404 | 0.200 |
Why?
|
| Blood | 2 | 2014 | 598 | 0.200 |
Why?
|
| Preventive Health Services | 2 | 2016 | 575 | 0.200 |
Why?
|
| Government Programs | 1 | 2023 | 275 | 0.200 |
Why?
|
| Disease Transmission, Infectious | 4 | 2021 | 547 | 0.200 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 1411 | 0.200 |
Why?
|
| Immunologic Memory | 4 | 2018 | 1348 | 0.200 |
Why?
|
| Vaginal Smears | 2 | 2014 | 511 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2018 | 4479 | 0.200 |
Why?
|
| Public Health Practice | 1 | 2003 | 218 | 0.190 |
Why?
|
| Primary Health Care | 1 | 2017 | 4558 | 0.190 |
Why?
|
| Age Factors | 5 | 2021 | 18370 | 0.190 |
Why?
|
| Simian immunodeficiency virus | 2 | 2017 | 846 | 0.190 |
Why?
|
| Betamethasone | 1 | 2020 | 45 | 0.190 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 6489 | 0.180 |
Why?
|
| Middle Aged | 33 | 2019 | 213383 | 0.180 |
Why?
|
| Metronidazole | 1 | 2021 | 217 | 0.180 |
Why?
|
| DNA, Viral | 2 | 2019 | 2225 | 0.180 |
Why?
|
| Antibody Specificity | 5 | 2020 | 1095 | 0.180 |
Why?
|
| Vulnerable Populations | 3 | 2015 | 687 | 0.180 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 1889 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 5 | 2020 | 6171 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 780 | 0.180 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2019 | 158 | 0.170 |
Why?
|
| Therapeutic Irrigation | 2 | 2015 | 301 | 0.170 |
Why?
|
| Risk Factors | 22 | 2023 | 72290 | 0.170 |
Why?
|
| Phylogeny | 8 | 2019 | 2803 | 0.170 |
Why?
|
| Risk-Taking | 4 | 2014 | 986 | 0.170 |
Why?
|
| Genotype | 7 | 2021 | 12951 | 0.170 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 291 | 0.170 |
Why?
|
| HIV Antigens | 2 | 2017 | 347 | 0.170 |
Why?
|
| Health Services Accessibility | 3 | 2014 | 5137 | 0.170 |
Why?
|
| Control Groups | 2 | 1998 | 105 | 0.170 |
Why?
|
| Students | 3 | 2014 | 1654 | 0.170 |
Why?
|
| Kenya | 3 | 2020 | 685 | 0.160 |
Why?
|
| Bacterial Translocation | 2 | 2021 | 73 | 0.160 |
Why?
|
| Bodily Secretions | 2 | 2015 | 23 | 0.160 |
Why?
|
| Antibodies | 2 | 2021 | 2460 | 0.160 |
Why?
|
| Gardnerella vaginalis | 1 | 2018 | 13 | 0.160 |
Why?
|
| Killer Cells, Natural | 4 | 2020 | 2133 | 0.160 |
Why?
|
| Health Resources | 3 | 2021 | 911 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2019 | 565 | 0.160 |
Why?
|
| Double-Blind Method | 7 | 2022 | 12026 | 0.150 |
Why?
|
| Cross-Sectional Studies | 13 | 2022 | 25043 | 0.150 |
Why?
|
| Abortion, Incomplete | 1 | 1997 | 13 | 0.150 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 153 | 0.150 |
Why?
|
| Antibody Affinity | 2 | 2015 | 254 | 0.150 |
Why?
|
| Plasma | 3 | 2019 | 575 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2012 | 3923 | 0.150 |
Why?
|
| Semen | 2 | 2021 | 316 | 0.150 |
Why?
|
| Uncertainty | 1 | 2022 | 734 | 0.150 |
Why?
|
| International Cooperation | 1 | 2023 | 1420 | 0.140 |
Why?
|
| Condoms, Female | 1 | 2016 | 8 | 0.140 |
Why?
|
| Chlamydia trachomatis | 3 | 2023 | 246 | 0.140 |
Why?
|
| Time Factors | 12 | 2021 | 40075 | 0.140 |
Why?
|
| Lymphocytes | 2 | 2016 | 2617 | 0.140 |
Why?
|
| Maternal Welfare | 1 | 1997 | 115 | 0.140 |
Why?
|
| Cyclophilin A | 1 | 2016 | 57 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2019 | 880 | 0.140 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 215 | 0.140 |
Why?
|
| Mobile Health Units | 1 | 1997 | 80 | 0.140 |
Why?
|
| Ethics, Medical | 2 | 2000 | 792 | 0.140 |
Why?
|
| Pregnant Women | 2 | 1998 | 568 | 0.140 |
Why?
|
| History, 20th Century | 2 | 2014 | 2740 | 0.140 |
Why?
|
| Gene Products, gag | 1 | 2017 | 337 | 0.140 |
Why?
|
| Immunization | 2 | 2019 | 1256 | 0.140 |
Why?
|
| Food Supply | 1 | 2021 | 524 | 0.140 |
Why?
|
| AIDS Serodiagnosis | 2 | 2012 | 184 | 0.130 |
Why?
|
| Neisseria gonorrhoeae | 3 | 2023 | 238 | 0.130 |
Why?
|
| Systems Integration | 1 | 2017 | 440 | 0.130 |
Why?
|
| Introns | 1 | 2018 | 991 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2016 | 113 | 0.130 |
Why?
|
| Hospitals, Public | 1 | 1997 | 207 | 0.130 |
Why?
|
| B-Lymphocytes | 5 | 2016 | 4665 | 0.130 |
Why?
|
| Transients and Migrants | 2 | 1997 | 155 | 0.130 |
Why?
|
| Interleukin-8 | 2 | 2015 | 690 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 3647 | 0.130 |
Why?
|
| Child Welfare | 2 | 2012 | 523 | 0.130 |
Why?
|
| Case-Control Studies | 9 | 2022 | 21746 | 0.130 |
Why?
|
| Health Policy | 4 | 2023 | 2661 | 0.130 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2014 | 87 | 0.130 |
Why?
|
| Directly Observed Therapy | 2 | 2006 | 137 | 0.120 |
Why?
|
| Virus Internalization | 1 | 2018 | 501 | 0.120 |
Why?
|
| Genes, Immunoglobulin | 1 | 2015 | 291 | 0.120 |
Why?
|
| Drug Evaluation | 2 | 2014 | 647 | 0.120 |
Why?
|
| Maternal Health Services | 2 | 2012 | 455 | 0.120 |
Why?
|
| Freedom | 1 | 2014 | 69 | 0.120 |
Why?
|
| Mass Screening | 3 | 2020 | 5255 | 0.120 |
Why?
|
| Immunity, Innate | 3 | 2016 | 2958 | 0.120 |
Why?
|
| Chromosomes, Human, Y | 1 | 2014 | 148 | 0.120 |
Why?
|
| Genes, MHC Class I | 1 | 2014 | 258 | 0.120 |
Why?
|
| Body Fluids | 1 | 2015 | 319 | 0.120 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 6895 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2019 | 1119 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2014 | 5078 | 0.110 |
Why?
|
| Integrins | 1 | 2018 | 846 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 2 | 2011 | 380 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 419 | 0.110 |
Why?
|
| Patient Rights | 1 | 2014 | 126 | 0.110 |
Why?
|
| Receptors, CCR5 | 1 | 2015 | 497 | 0.110 |
Why?
|
| Contraceptive Devices, Male | 1 | 1992 | 13 | 0.110 |
Why?
|
| Community-Based Participatory Research | 1 | 2015 | 214 | 0.110 |
Why?
|
| Health Services | 3 | 2012 | 758 | 0.110 |
Why?
|
| Community Networks | 1 | 2015 | 203 | 0.110 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 12072 | 0.110 |
Why?
|
| Acute Disease | 5 | 2016 | 7149 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2018 | 8324 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 4 | 2017 | 5391 | 0.110 |
Why?
|
| Prenatal Care | 4 | 2004 | 1092 | 0.110 |
Why?
|
| Interleukin-17 | 2 | 2015 | 899 | 0.110 |
Why?
|
| Urine | 1 | 2014 | 370 | 0.110 |
Why?
|
| Exons | 1 | 2018 | 2437 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 617 | 0.110 |
Why?
|
| HIV Core Protein p24 | 1 | 2012 | 256 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 1676 | 0.110 |
Why?
|
| Macaca mulatta | 2 | 2017 | 2375 | 0.110 |
Why?
|
| Haplotypes | 2 | 2016 | 2779 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 634 | 0.100 |
Why?
|
| Education, Medical | 1 | 2004 | 1721 | 0.100 |
Why?
|
| Alleles | 4 | 2016 | 6933 | 0.100 |
Why?
|
| Sputum | 1 | 2014 | 476 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2015 | 648 | 0.100 |
Why?
|
| Hepatitis D | 1 | 1991 | 18 | 0.100 |
Why?
|
| Biotransformation | 1 | 2011 | 168 | 0.100 |
Why?
|
| Nevirapine | 2 | 2003 | 267 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 7181 | 0.100 |
Why?
|
| Patient Compliance | 4 | 2010 | 2684 | 0.100 |
Why?
|
| Administration, Topical | 2 | 2012 | 690 | 0.100 |
Why?
|
| Tablets | 1 | 2012 | 145 | 0.100 |
Why?
|
| Measles Vaccine | 1 | 1991 | 76 | 0.100 |
Why?
|
| Animals | 12 | 2023 | 168757 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2016 | 525 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 1997 | 969 | 0.100 |
Why?
|
| Licensure | 1 | 2012 | 124 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 319 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2021 | 1836 | 0.100 |
Why?
|
| Health Education | 5 | 2003 | 1056 | 0.100 |
Why?
|
| Reproductive Health Services | 1 | 2012 | 80 | 0.100 |
Why?
|
| Quality Improvement | 2 | 2017 | 3749 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2015 | 2327 | 0.100 |
Why?
|
| Germ Cells | 1 | 2015 | 631 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1790 | 0.090 |
Why?
|
| Half-Life | 1 | 2011 | 661 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2021 | 4026 | 0.090 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1991 | 118 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2003 | 3022 | 0.090 |
Why?
|
| Recurrence | 3 | 2021 | 8340 | 0.090 |
Why?
|
| Amino Acid Sequence | 8 | 2017 | 13815 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 4 | 2021 | 1477 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2023 | 14722 | 0.090 |
Why?
|
| Personal Satisfaction | 1 | 2014 | 643 | 0.090 |
Why?
|
| Program Evaluation | 2 | 2014 | 2488 | 0.090 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 13989 | 0.090 |
Why?
|
| Antibody Diversity | 1 | 2009 | 74 | 0.090 |
Why?
|
| Immunization Schedule | 1 | 1991 | 221 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2012 | 981 | 0.090 |
Why?
|
| Cell Movement | 3 | 2016 | 5217 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1200 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2015 | 1364 | 0.090 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 1586 | 0.090 |
Why?
|
| DNA Methylation | 2 | 2021 | 4286 | 0.090 |
Why?
|
| Physician's Role | 1 | 1996 | 943 | 0.080 |
Why?
|
| Th17 Cells | 1 | 2015 | 766 | 0.080 |
Why?
|
| Logistic Models | 5 | 2018 | 13408 | 0.080 |
Why?
|
| Integrases | 1 | 2011 | 533 | 0.080 |
Why?
|
| Drug Interactions | 2 | 2011 | 1460 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2014 | 1462 | 0.080 |
Why?
|
| Sample Size | 1 | 2012 | 845 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2015 | 3588 | 0.080 |
Why?
|
| Violence | 2 | 2012 | 909 | 0.080 |
Why?
|
| School Health Services | 1 | 2012 | 375 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 323 | 0.080 |
Why?
|
| Peptide Fragments | 3 | 2018 | 5097 | 0.080 |
Why?
|
| Molecular Sequence Data | 8 | 2014 | 18111 | 0.080 |
Why?
|
| Disclosure | 1 | 2014 | 736 | 0.080 |
Why?
|
| Research | 4 | 2018 | 1999 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2012 | 732 | 0.080 |
Why?
|
| Communication | 1 | 2022 | 3749 | 0.080 |
Why?
|
| United States | 6 | 2023 | 69872 | 0.080 |
Why?
|
| Cytidine Deaminase | 1 | 2010 | 252 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 1587 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2014 | 1534 | 0.080 |
Why?
|
| Zambia | 2 | 2020 | 261 | 0.080 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 1265 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 12354 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2017 | 2564 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 3870 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 3 | 2021 | 2012 | 0.070 |
Why?
|
| Virulence | 2 | 2021 | 1333 | 0.070 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 724 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 847 | 0.070 |
Why?
|
| Infant | 10 | 2006 | 35136 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2012 | 1959 | 0.070 |
Why?
|
| India | 2 | 2010 | 2197 | 0.070 |
Why?
|
| Data Collection | 1 | 1996 | 3341 | 0.070 |
Why?
|
| Child, Institutionalized | 1 | 1988 | 108 | 0.070 |
Why?
|
| Intestines | 1 | 2016 | 1924 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1991 | 454 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 4803 | 0.070 |
Why?
|
| Saquinavir | 1 | 2006 | 28 | 0.070 |
Why?
|
| World Health Organization | 1 | 2012 | 1318 | 0.070 |
Why?
|
| Flow Cytometry | 5 | 2018 | 5974 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 15519 | 0.070 |
Why?
|
| Educational Status | 1 | 2014 | 2540 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2886 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 2942 | 0.070 |
Why?
|
| Drug Approval | 1 | 2012 | 742 | 0.070 |
Why?
|
| Schools | 1 | 2014 | 1433 | 0.070 |
Why?
|
| Cross Reactions | 3 | 2013 | 841 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10180 | 0.070 |
Why?
|
| Viremia | 2 | 2019 | 736 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 2021 | 5021 | 0.060 |
Why?
|
| Cell Line | 5 | 2021 | 15997 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2015 | 3200 | 0.060 |
Why?
|
| Penicillin G Benzathine | 1 | 2004 | 24 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2015 | 3209 | 0.060 |
Why?
|
| Complementarity Determining Regions | 2 | 2017 | 149 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2016 | 2725 | 0.060 |
Why?
|
| Needle Sharing | 1 | 2004 | 24 | 0.060 |
Why?
|
| Social Support | 1 | 2015 | 2118 | 0.060 |
Why?
|
| Evidence-Based Practice | 1 | 2009 | 500 | 0.060 |
Why?
|
| Pregnancy Outcome | 3 | 2010 | 2795 | 0.060 |
Why?
|
| Stereotyping | 1 | 2007 | 241 | 0.060 |
Why?
|
| Geography | 1 | 2007 | 669 | 0.060 |
Why?
|
| Motivation | 1 | 2014 | 1971 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2014 | 6459 | 0.060 |
Why?
|
| Breast Feeding | 2 | 2003 | 1338 | 0.060 |
Why?
|
| Syringes | 1 | 2004 | 56 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1831 | 0.060 |
Why?
|
| Africa, Southern | 1 | 2023 | 57 | 0.060 |
Why?
|
| Infant, Newborn | 9 | 2004 | 25625 | 0.060 |
Why?
|
| Genome, Viral | 2 | 2021 | 667 | 0.060 |
Why?
|
| Ritonavir | 1 | 2006 | 322 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2015 | 4217 | 0.060 |
Why?
|
| Monocytes | 1 | 2013 | 2596 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 1991 | 305 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2020 | 956 | 0.060 |
Why?
|
| Hepatitis Antibodies | 2 | 1993 | 73 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 4420 | 0.060 |
Why?
|
| Heterosexuality | 2 | 2018 | 276 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2021 | 19229 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2009 | 1609 | 0.060 |
Why?
|
| HIV Protease Inhibitors | 1 | 2006 | 430 | 0.060 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 77 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2011 | 5179 | 0.060 |
Why?
|
| Deoxyadenosines | 1 | 2022 | 27 | 0.060 |
Why?
|
| Sex Factors | 4 | 2010 | 10397 | 0.060 |
Why?
|
| Child | 13 | 2014 | 77709 | 0.050 |
Why?
|
| Hepatitis C | 1 | 1993 | 1591 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2014 | 3023 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 2 | 2014 | 401 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2022 | 112 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2015 | 421 | 0.050 |
Why?
|
| Syphilis | 1 | 2004 | 227 | 0.050 |
Why?
|
| Child, Preschool | 10 | 1997 | 41006 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2009 | 2715 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2716 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2017 | 2011 | 0.050 |
Why?
|
| Solvents | 1 | 2022 | 302 | 0.050 |
Why?
|
| Therapeutic Human Experimentation | 2 | 1998 | 43 | 0.050 |
Why?
|
| Prisoners | 1 | 2004 | 297 | 0.050 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2006 | 810 | 0.050 |
Why?
|
| Women's Health | 1 | 2010 | 2034 | 0.050 |
Why?
|
| Phytohemagglutinins | 1 | 2020 | 170 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2017 | 23338 | 0.050 |
Why?
|
| Zimbabwe | 2 | 2015 | 129 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 2916 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2018 | 1880 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2017 | 2256 | 0.050 |
Why?
|
| Public Sector | 2 | 2012 | 265 | 0.050 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 68 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2009 | 2616 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 3846 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.050 |
Why?
|
| Patient Selection | 1 | 2012 | 4215 | 0.050 |
Why?
|
| Nonoxynol | 1 | 1999 | 12 | 0.040 |
Why?
|
| Spermatocidal Agents | 1 | 1999 | 15 | 0.040 |
Why?
|
| Leadership | 1 | 2009 | 1357 | 0.040 |
Why?
|
| Biological Assay | 1 | 2023 | 652 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 434 | 0.040 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 262 | 0.040 |
Why?
|
| Interleukin-1beta | 2 | 2015 | 972 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2018 | 11483 | 0.040 |
Why?
|
| Drug Packaging | 1 | 1999 | 39 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2021 | 77449 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 862 | 0.040 |
Why?
|
| Research Subjects | 2 | 1998 | 239 | 0.040 |
Why?
|
| Ambulatory Care | 2 | 2010 | 2708 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 236 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 12245 | 0.040 |
Why?
|
| Virus Latency | 1 | 2021 | 358 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 275 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2017 | 6196 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2019 | 182 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 15540 | 0.040 |
Why?
|
| Social Justice | 1 | 2023 | 456 | 0.040 |
Why?
|
| Prognosis | 4 | 2022 | 29063 | 0.040 |
Why?
|
| DNA Primers | 2 | 2014 | 2892 | 0.040 |
Why?
|
| Ethical Review | 1 | 1998 | 26 | 0.040 |
Why?
|
| Anemia | 1 | 2008 | 1506 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2021 | 881 | 0.040 |
Why?
|
| Models, Biological | 2 | 2011 | 9583 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2018 | 4204 | 0.040 |
Why?
|
| Hepatitis B Antibodies | 2 | 1989 | 159 | 0.040 |
Why?
|
| Circumcision, Male | 1 | 2019 | 150 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 19905 | 0.040 |
Why?
|
| Gardnerella | 1 | 2017 | 2 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2009 | 1797 | 0.040 |
Why?
|
| Developed Countries | 1 | 2000 | 437 | 0.040 |
Why?
|
| Age Distribution | 2 | 2012 | 2902 | 0.040 |
Why?
|
| Oxazines | 1 | 2018 | 298 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 1681 | 0.040 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2018 | 142 | 0.030 |
Why?
|
| Health Surveys | 2 | 2019 | 4037 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 1956 | 0.030 |
Why?
|
| Poverty | 2 | 2018 | 2660 | 0.030 |
Why?
|
| Lactobacillus | 1 | 2017 | 189 | 0.030 |
Why?
|
| Amino Acids | 1 | 2022 | 1736 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2016 | 253 | 0.030 |
Why?
|
| Cell Separation | 2 | 2012 | 1751 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2020 | 1035 | 0.030 |
Why?
|
| Amino Acid Motifs | 2 | 2009 | 936 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2019 | 541 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 976 | 0.030 |
Why?
|
| Fees and Charges | 1 | 1997 | 195 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2016 | 147 | 0.030 |
Why?
|
| Resource Allocation | 1 | 1998 | 341 | 0.030 |
Why?
|
| Immunity | 1 | 2022 | 1012 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 1998 | 298 | 0.030 |
Why?
|
| State Medicine | 1 | 1997 | 217 | 0.030 |
Why?
|
| Uganda | 1 | 2020 | 1243 | 0.030 |
Why?
|
| Antigenic Variation | 1 | 2015 | 125 | 0.030 |
Why?
|
| Causality | 1 | 2022 | 1275 | 0.030 |
Why?
|
| Chemokine CCL20 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Sterilization, Tubal | 1 | 2015 | 87 | 0.030 |
Why?
|
| Referral and Consultation | 3 | 1997 | 3528 | 0.030 |
Why?
|
| Virus Attachment | 1 | 2015 | 55 | 0.030 |
Why?
|
| Comorbidity | 1 | 2009 | 10388 | 0.030 |
Why?
|
| Confidentiality | 1 | 1999 | 612 | 0.030 |
Why?
|
| Malawi | 1 | 2015 | 282 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3597 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2020 | 1539 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 304 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 2015 | 377 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2016 | 9146 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2012 | 1821 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1590 | 0.030 |
Why?
|
| Biodiversity | 1 | 2017 | 341 | 0.030 |
Why?
|
| Evolution, Molecular | 2 | 2014 | 1940 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 552 | 0.030 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2015 | 188 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2016 | 9849 | 0.030 |
Why?
|
| Chromates | 1 | 1993 | 7 | 0.030 |
Why?
|
| Quinazolines | 1 | 2021 | 1356 | 0.030 |
Why?
|
| Hepatovirus | 1 | 1993 | 50 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2019 | 2008 | 0.030 |
Why?
|
| Hepatitis A Antibodies | 1 | 1993 | 18 | 0.030 |
Why?
|
| Kinetics | 2 | 2012 | 6473 | 0.030 |
Why?
|
| Gene Products, env | 1 | 2015 | 263 | 0.030 |
Why?
|
| Drug Industry | 1 | 2000 | 746 | 0.030 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1994 | 138 | 0.030 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 97 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4751 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2021 | 3913 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 1126 | 0.030 |
Why?
|
| Chemical Industry | 1 | 1993 | 114 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 954 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 1157 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2021 | 1951 | 0.030 |
Why?
|
| Pyridones | 1 | 2018 | 712 | 0.030 |
Why?
|
| Social Class | 1 | 2002 | 1999 | 0.030 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 491 | 0.030 |
Why?
|
| Nose Diseases | 1 | 1993 | 79 | 0.030 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 1 | 2012 | 1 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 2007 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2015 | 362 | 0.030 |
Why?
|
| Alphavirus | 1 | 2012 | 9 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 1998 | 392 | 0.030 |
Why?
|
| Candidiasis | 1 | 2015 | 366 | 0.030 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2013 | 90 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2014 | 298 | 0.030 |
Why?
|
| Healthy People Programs | 1 | 2012 | 53 | 0.030 |
Why?
|
| Nasal Septum | 1 | 1993 | 127 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 5456 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2012 | 130 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 659 | 0.030 |
Why?
|
| Administration, Rectal | 1 | 2011 | 73 | 0.030 |
Why?
|
| Avian Proteins | 1 | 2012 | 80 | 0.030 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2013 | 172 | 0.030 |
Why?
|
| HIV-2 | 1 | 1992 | 167 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2017 | 1402 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 1991 | 7659 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2017 | 914 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 903 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2015 | 669 | 0.030 |
Why?
|
| Space-Time Clustering | 1 | 1991 | 49 | 0.030 |
Why?
|
| Risk | 2 | 2018 | 9687 | 0.030 |
Why?
|
| Anonymous Testing | 1 | 1991 | 8 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2011 | 12208 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2015 | 2050 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 300 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1997 | 1877 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2012 | 212 | 0.020 |
Why?
|
| Microbial Viability | 1 | 2012 | 234 | 0.020 |
Why?
|
| Immunoassay | 1 | 2015 | 752 | 0.020 |
Why?
|
| Fluorescein | 1 | 2011 | 171 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 1681 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 354 | 0.020 |
Why?
|
| Financing, Organized | 1 | 2012 | 202 | 0.020 |
Why?
|
| Students, Medical | 1 | 2004 | 1862 | 0.020 |
Why?
|
| Curriculum | 1 | 2004 | 3605 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1413 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 274 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2015 | 694 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2282 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2017 | 3128 | 0.020 |
Why?
|
| Urban Health | 2 | 1995 | 547 | 0.020 |
Why?
|
| Mandatory Programs | 1 | 1991 | 87 | 0.020 |
Why?
|
| Tanzania | 1 | 2014 | 1346 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2014 | 542 | 0.020 |
Why?
|
| Interviews as Topic | 2 | 2014 | 2539 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 3768 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2015 | 6544 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2203 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 781 | 0.020 |
Why?
|
| Private Sector | 1 | 2012 | 392 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1588 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2009 | 80 | 0.020 |
Why?
|
| Adsorption | 1 | 2009 | 201 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
| Botswana | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 940 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 1723 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 809 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 15076 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 2959 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 468 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1998 | 2052 | 0.020 |
Why?
|
| Hospitalization | 2 | 2023 | 10262 | 0.020 |
Why?
|
| Hepatitis B Antigens | 1 | 1988 | 40 | 0.020 |
Why?
|
| Pediatrics | 2 | 2016 | 3475 | 0.020 |
Why?
|
| Mothers | 2 | 2004 | 2165 | 0.020 |
Why?
|
| ROC Curve | 1 | 2015 | 3527 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Culicidae | 1 | 1988 | 105 | 0.020 |
Why?
|
| Virion | 1 | 2010 | 433 | 0.020 |
Why?
|
| Piperazines | 1 | 2018 | 2488 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 725 | 0.020 |
Why?
|
| Community Health Services | 1 | 1992 | 650 | 0.020 |
Why?
|
| Proteome | 1 | 2017 | 1799 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 4217 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2015 | 1401 | 0.020 |
Why?
|
| Culex | 1 | 1986 | 19 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 6622 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 2297 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 3036 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2011 | 2839 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2007 | 258 | 0.020 |
Why?
|
| Chimera | 1 | 2007 | 485 | 0.020 |
Why?
|
| Family Health | 1 | 1991 | 1282 | 0.020 |
Why?
|
| Patient Participation | 1 | 2015 | 1457 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1996 | 1832 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 2216 | 0.020 |
Why?
|
| Program Development | 1 | 2012 | 1316 | 0.020 |
Why?
|
| Hepacivirus | 1 | 1993 | 1379 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 1904 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1993 | 1471 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 6114 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 2504 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 1836 | 0.020 |
Why?
|
| Point Mutation | 1 | 2010 | 1623 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 1861 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 3462 | 0.010 |
Why?
|
| Cicatrix | 1 | 1989 | 764 | 0.010 |
Why?
|
| Self Report | 1 | 2014 | 3558 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 3610 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 6309 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1993 | 2759 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17446 | 0.010 |
Why?
|
| Proteomics | 1 | 2015 | 3638 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2008 | 1534 | 0.010 |
Why?
|
| Contraception Behavior | 1 | 2003 | 185 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2014 | 10252 | 0.010 |
Why?
|
| Maternal Age | 1 | 2003 | 802 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 16689 | 0.010 |
Why?
|
| Epidemiologic Research Design | 1 | 2003 | 367 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 2400 | 0.010 |
Why?
|
| Base Sequence | 1 | 2011 | 12797 | 0.010 |
Why?
|
| Infant Mortality | 1 | 2004 | 754 | 0.010 |
Why?
|
| Apoptosis | 1 | 2016 | 9727 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2011 | 3589 | 0.010 |
Why?
|
| Peptides | 1 | 2011 | 4409 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 9438 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1997 | 5319 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1186 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1992 | 3843 | 0.010 |
Why?
|
| Voluntary Programs | 1 | 1998 | 42 | 0.010 |
Why?
|
| Population Control | 1 | 1997 | 20 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 3158 | 0.010 |
Why?
|
| Fees, Medical | 1 | 1997 | 117 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10481 | 0.010 |
Why?
|
| Aging | 1 | 2015 | 8664 | 0.010 |
Why?
|
| Ethics Committees, Research | 1 | 1998 | 194 | 0.010 |
Why?
|
| Algorithms | 1 | 2017 | 13881 | 0.010 |
Why?
|
| Social Problems | 1 | 1995 | 112 | 0.010 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 1997 | 336 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 13033 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 2029 | 0.010 |
Why?
|
| Ethics Committees | 1 | 1992 | 54 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2012 | 6600 | 0.010 |
Why?
|
| Ulcer | 1 | 1993 | 209 | 0.010 |
Why?
|
| Population Dynamics | 1 | 1992 | 302 | 0.010 |
Why?
|
| Schools, Medical | 1 | 1997 | 880 | 0.010 |
Why?
|
| Aged | 2 | 2014 | 163280 | 0.010 |
Why?
|
| Education, Medical, Undergraduate | 1 | 1997 | 1008 | 0.000 |
Why?
|
| Forecasting | 1 | 1997 | 2951 | 0.000 |
Why?
|
| Health Care Reform | 1 | 1997 | 1261 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1989 | 57776 | 0.000 |
Why?
|
| Malaria | 1 | 1992 | 1239 | 0.000 |
Why?
|
| Internship and Residency | 1 | 1997 | 5788 | 0.000 |
Why?
|